Main Menu

Turning Point Therapeutics, Inc.

(NASDAQ GS: TPTX)

Rigrodsky Law, P.A. is investigating Turning Point Therapeutics, Inc. (“Turning Point”) regarding possible breaches of fiduciary duties and other violations of law related to Turning Point’s agreement to be acquired by Bristol-Myers Squibb Company (NYSE: BMY). Under the terms of the agreement Turning Point’s shareholders will receive $76.00 in cash for each share of Turning Point common stock they own.

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to info@rl-legal.com.

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 07/06/2022


* Indicates a required field.

Back to Page